Cited by 565Pain Mechanisms and TreatmentsPain Management and TreatmentPain Management and Opioid Use

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

Open access

Lunn, Michael PT, Hughes, Richard AC, Wiffen, Philip J·2014·Cochrane Database of Systematic Reviews

DOI 10.1002/14651858.cd007115.pub3PMC PMC10711341

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Duloxetine is a balanced serotonin and noradrenaline reuptake inhibitor licensed for the treatment of major depressive disorders, urinary stress incontinence and the management of neuropathic pain associated with diabetic peripheral neuropathy. A number of trials have been conducted to investigate the use of duloxetine in neuropathic and nociceptive painful conditions. This is the first update of a review first published in 2010. OBJECTIVES: To assess the benefits and harms of duloxetine for treating painful neuropathy and different types of chronic pain. SEARCH METHODS: On 19th November 2013, we searched The Cochrane Neuromuscular Group Specialized Register, CENTRAL, DARE, HTA, NHSEED, MEDLINE, and EMBASE. We searched ClinicalTrials.gov for ongoing trials in April 2013. We also searched the reference lists of identified publications for trials of duloxetine for the treatment of painful peripheral neuropathy or chronic pain. SELECTION CRITERIA: We selected all randomised or quasi-randomised trials of any formulation of duloxetine, used for the treatment of painful peripheral neuropathy or chronic pain in adults. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by The Cochrane Collaboration. MAIN RESULTS: We identified 18 trials, which included 6407 participants. We found 12 of these studies in the literature search for this update. Eight studies included a total of 2728 participants with painful diabetic neuropathy and six studies involved 2249 participants with fibromyalgia. Three studies included participants with depression and painful physical symptoms and one included participants with central neuropathic pain. Studies were mostly at low risk of bias, although significant drop outs, imputation methods and almost every study being performed or sponsored by the drug manufacturer add to the risk of bias in some domains. Duloxetine at 60 mg daily is effective in treating painful diabetic peripheral neuropathy in the short term, with a risk ratio (RR) for ≥ 50% pain reduction at 12 weeks of 1.73 (95% CI 1.44 to 2.08). The related NNTB is 5 (95% CI 4 to 7). Duloxetine at 60 mg daily is also effective for fibromyalgia over 12 weeks (RR for ≥ 50% reduction in pain 1.57, 95% CI 1.20 to 2.06; NNTB 8, 95% CI 4 to 21) and over 28 weeks (RR 1.58, 95% CI 1.10 to 2.27) as well as for painful physical symptoms in depression (RR 1.37, 95% CI 1.19 to 1.59; NNTB 8, 95% CI 5 to 14). There was no effect on central neuropathic pain in a single, small, high quality trial. In all conditions, adverse events were common in both treatment and placebo arms but more common in the treatment arm, with a dose-dependent effect. Most adverse effects were minor, but 16% of participants stopped the drug due to adverse effects. Serious adverse events were rare. AUTHORS' CONCLUSIONS: There is adequate amounts of moderate quality evidence from eight studies performed by the manufacturers of duloxetine that doses of 60 mg and 120 mg daily are efficacious for treating pain in diabetic peripheral neuropathy but lower daily doses are not. Further trials are not required. In fibromyalgia, there is lower quality evidence that duloxetine is effective at similar doses to those used in diabetic peripheral neuropathy and with a similar magnitude of effect. The effect in fibromyalgia may be achieved through a greater improvement in mental symptoms than in somatic physical pain. There is low to moderate quality evidence that pain relief is also achieved in pain associated with depressive symptoms, but the NNTB of 8 in fibromyalgia and depression is not an indication of substantial efficacy. More trials (preferably independent investigator led studies) in these indications are required to reach an optimal information size to make convincing determinations of efficacy.Minor side effects are common and more common with duloxetine 60 mg and particularly with 120 mg daily, than 20 mg daily, but serious side effects are rare.Improved direct comparisons of duloxetine with other antidepressants and with other drugs, such as pregabalin, that have already been shown to be efficacious in neuropathic pain would be appropriate. Unbiased economic comparisons would further help decision making, but no high quality study includes economic data.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/14651858.cd007115.pub3

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2 retracted

Gabapentin for acute and chronic pain
Wiffen, P. J., McQuay, H. J., Edwards, J. E., & Moore, R. A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005452 · Cited by 247
Self-citation
Retracted
Gabapentin for acute and chronic pain
Wiffen, P. J., McQuay, H. J., Edwards, J. E., & Moore, R. A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005452.pub2 · Cited by 230
Self-citation
Retracted
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,369
Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006) · European Journal of Pain · doi:10.1016/j.ejpain.2005.06.009 · Cited by 5,486
Untitled work
(2008) · Cited by 3,790
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Untitled work
Treede (2008) · doi:10.1212/01.wnl.0000282763.29778.59 · Cited by 2,746
Self-citation
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Untitled work
(1991) · PubMed · Cited by 1,837
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale
Salaffi, F., Stancati, A., Silvestri, C. A., Ciapetti, A., & Grassi, W. (2003) · European Journal of Pain · doi:10.1016/j.ejpain.2003.09.004 · Cited by 1,735
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
Smith, E., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Ahles, T. A., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,016
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M. L., Hansson, P. T., Jensen, T. S., Nurmikko, T. J., Sampaio, C., Sindrup, S. H., & Wiffen, P. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 877
Self-citation
Duloxetine vs. placebo in patients with painful diabetic neuropathy
GOLDSTEIN, D. J., Lu, Y., Detke, M. J., Lee, T. C., & Iyengar, S. (2005) · Pain · doi:10.1016/j.pain.2005.03.029 · Cited by 861
Antidepressants for neuropathic pain
Saarto, T., & Wiffen, P. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005454.pub2 · Cited by 806
Self-citation
Pregabalin for acute and chronic pain in adults
Moore, R. A., Straube, S., Wiffen, P. J., Derry, S., & McQuay, H. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub2 · Cited by 786
Self-citation
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Bymaster, F. P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 725
The Intention-to-Treat Principle: How to Assess the True Effect of Choosing a Medical Treatment
Detry, M. A., & Lewis, R. J. (2014) · JAMA · doi:10.1001/jama.2014.7523 · Cited by 634
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624
A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain
Raskin, J., Pritchett, Y., Wang, F., D’Souza, D. N., Waninger, A., Iyengar, S., & Wernicke, J. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00061.x · Cited by 539
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
Wernicke, J. F., Pritchett, Y., D’Souza, D. N., Waninger, A., Tran, P., Iyengar, S., & Raskin, J. (2006) · Neurology · doi:10.1212/01.wnl.0000240225.04000.1a · Cited by 514
A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder
Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471
Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes
Daousi, C., MacFarlane, I. A., Woodward, A., Nurmikko, T. J., Bundred, P. E., & Benbow, S. J. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01271.x · Cited by 459
Epidemiology and treatment of neuropathic pain: The UK primary care perspective
Hall, G. C., Carroll, D., Parry, D., & McQuay, H. J. (2006) · Pain · doi:10.1016/j.pain.2006.01.030 · Cited by 384
Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial ☆
Russell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
Duloxetine in the Treatment of Depression: A Double-Blind Placebo-Controlled Comparison With Paroxetine
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain
Tesfaye, S., Wilhelm, S., Lledo, A., Schacht, A., Tölle, T., Bouhassira, D., Cruccu, G., Skljarevski, V., & Freynhagen, R. (2013) · Pain · doi:10.1016/j.pain.2013.05.043 · Cited by 311
Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial
Chappell, A. S., Ossanna, M. J., Liu‐Seifert, H., Iyengar, S., Skljarevski, V., LI, L. C., Bennett, R. M., & Collins, H. (2009) · Pain · doi:10.1016/j.pain.2009.06.024 · Cited by 295
Amitriptyline for neuropathic pain and fibromyalgia in adults
Moore, R. A., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008242.pub2 · Cited by 293
Self-citation
Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxetine, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain
Boyle, J., Eriksson, M., Gribble, L., Gouni, R., Johnsen, S., Coppini, D., & Kerr, D. E. (2012) · Diabetes Care · doi:10.2337/dc12-0656 · Cited by 236
A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee
Chappell, A. S., Desaiah, D., Liu‐Seifert, H., Zhang, S., Skljarevski, V., Belenkov, Y., & Brown, J. P. (2010) · Pain Practice · doi:10.1111/j.1533-2500.2010.00401.x · Cited by 221
Side effects of drugs
Meyler, L. (1952) · Elsevier eBooks · Cited by 220
The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients
D, M. F. M., Mallinckrodt, C. H., Detke, M. J., Watkin, J. G., & Wohlreich, M. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0411 · Cited by 211
Duloxetine Versus Placebo in Patients With Chronic Low Back Pain: A 12-Week, Fixed-Dose, Randomized, Double-Blind Trial
Skljarevski, V., Zhang, S., Desaiah, D., Alaka, K., Palacios, S., Miazgowski, T., & Patrick, K. (2010) · Journal of Pain · doi:10.1016/j.jpain.2010.03.002 · Cited by 201
Duloxetine for treating painful neuropathy or chronic pain
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub2 · Cited by 198
Self-citation
Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain
Skljarevski, V., Desaiah, D., Liu‐Seifert, H., Zhang, Q., Chappell, A. S., Detke, M. J., Iyengar, S., Atkinson, J. H., & Bačkonja, M. (2010) · Spine · doi:10.1097/brs.0b013e3181d3cef6 · Cited by 190
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder
Brannan, S. K., Mallinckrodt, C. H., Brown, E. B., Wohlreich, M. M., Watkin, J. G., & Schatzberg, A. F. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.04.011 · Cited by 180
Duloxetine versus other anti-depressive agents for depression
Cipriani, A., Koesters, M., Furukawa, T. A., Nosè, M., Purgato, M., Omori, I. M., Trespidi, C., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006533.pub2 · Cited by 172
Estimation of minimum clinically important difference for pain in fibromyalgia
Mease, P. J., Spaeth, M., Clauw, D. J., Arnold, L. M., Bradley, L. A., Russell, I. J., Kajdasz, D. K., Walker, D. J., & Chappell, A. S. (2011) · Arthritis Care & Research · doi:10.1002/acr.20449 · Cited by 171
A double‐blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain
Skljarevski, V., Ossanna, M. J., Liu‐Seifert, H., Zhang, Q., Chappell, A. S., Iyengar, S., Detke, M. J., & Backonja, M. M. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02648.x · Cited by 165
The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression
Bymaster, F. P., Lee, T., Knadler, M. P., Detke, M. J., & Iyengar, S. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764805 · Cited by 148
Antidepressants for neuropathic pain
Saarto, T., & Wiffen, P. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005454 · Cited by 142
Self-citation
Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies
Kajdasz, D. K., Iyengar, S., Desaiah, D., Bačkonja, M.-M., Farrar, J. T., Fishbain, D. A., Jensen, T. S., Rowbotham, M. C., Sang, C. N.-M., Ziegler, D., et al. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.002 · Cited by 141
Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults
Mariappan, P., Alhasso, A. A., GRANT, A. M., & N'Dow, J. M. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004742.pub2 · Cited by 140
Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial
Vranken, J. H., Hollmann, M. W., van der Vegt, M. H., Kruis, M. R., Heesen, M. A., Vos, K., Pijl, A. J., & Dijkgraaf, M. G. W. (2010) · Pain · doi:10.1016/j.pain.2010.09.005 · Cited by 135
Duloxetine, Pregabalin, and Duloxetine Plus Gabapentin for Diabetic Peripheral Neuropathic Pain Management in Patients With Inadequate Pain Response to Gabapentin: An Open-Label, Randomized, Noninferiority Comparison
Tanenberg, R. J., Irving, G. A., Risser, R. C., AHL, J. S. B., Robinson, M. J., Skljarevski, V., & Malcolm, S. K. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0681 · Cited by 133
An Evaluation of the Cardiovascular Safety Profile of Duloxetine
Wernicke, J., Lled, A., Raskin, J., Kajdasz, D. K., & Wang, F. (2007) · Drug Safety · doi:10.2165/00002018-200730050-00007 · Cited by 132
Duloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain
Raskin, J., Smith, T. R., Wong, K., Pritchett, Y., D’Souza, D. N., Iyengar, S., & Wernicke, J. (2006) · Journal of Palliative Medicine · doi:10.1089/jpm.2006.9.29 · Cited by 118
A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy
Kaur, H., Hota, D., Bhansali, A. K., Dutta, P. R., Bansal, D., & Chakrabarti, A. (2011) · Diabetes Care · doi:10.2337/dc10-1793 · Cited by 113
A retrospective pooled analysis of duloxetine safety in 23 983 subjects
Gahimer, J., Wernicke, J., Yalcin, I., Ossanna, M. J., Wulster-Radcliffe, M. C., & Viktrup, L. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x162719 · Cited by 102
A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia
Chappell, A. S. (2008) · International Journal of General Medicine · doi:10.2147/ijgm.s3979 · Cited by 100
Duloxetine for Patients with Diabetic Peripheral Neuropathic Pain: A 6-Month Open-Label Safety Study
Raskin, J., Wang, F., Pritchett, Y., & GOLDSTEIN, D. J. (2006) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00207.x · Cited by 98
Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
David, P., Pritchett, Y., Desaiah, D., & Raskin, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000224782.83287.3c · Cited by 94
Post Herpetic Neuralgia
Philip, A. G., & Thakur, R. (2011) · Journal of Palliative Medicine · doi:10.1089/jpm.2011.9685 · Cited by 90
Efficacy and Safety of Duloxetine 60 mg Once Daily in the Treatment of Pain in Patients With Major Depressive Disorder and At Least Moderate Pain of Unknown Etiology
Brecht, S., & Courtecuisse, C. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1110 · Cited by 89
Therapy Insight: fibromyalgia—a different type of pain needing a different type of treatment
Dadabhoy, D., & Clauw, D. J. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0221 · Cited by 89
Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial
Arnold, L. M., Clauw, D. J., WANG, F., AHL, J. S. B., Gaynor, P. J., & Wohlreich, M. M. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100365 · Cited by 80
Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan
Yasuda, H., Hotta, N., Nakao, K., Kasuga, M., Kashiwagi, A., & Kawamori, R. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00073.x · Cited by 65
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Duloxetine for the Treatment of Pain in Patients with Multiple Sclerosis
Vollmer, T. L., Robinson, M. J., Risser, R. C., & Malcolm, S. K. (2013) · Pain Practice · doi:10.1111/papr.12127 · Cited by 64
Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain
Rowbotham, M. C., Arslanian, A., Nothaft, W., Duan, R. W., Best, A. E., Pritchett, Y., Zhou, Q., & Stacey, B. R. (2012) · Pain · doi:10.1016/j.pain.2012.01.009 · Cited by 52
Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China.
Gao, Y., Ning, G., Jia, W., Zhou, Z., Xu, Z.-R., Liu, Z.-M., Liu, C., Ma, J., Li, Q., Cheng, L. L., et al. (2010) · PubMed · Cited by 47
Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain
Skljarevski, V., Desaiah, D., Zhang, Q., Chappell, A. S., Detke, M. J., Gross, J. L., & Ziegler, D. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1000 · Cited by 43
What do we know about duloxetine's mode of action? Evidence from animals to humans
Schuessler, B. (2006) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00877.x · Cited by 41
Cost-Effectiveness of Duloxetine Versus Routine Treatment for U.S. Patients With Diabetic Peripheral Neuropathic Pain
Wu, E. Q., Birnbaum, H. G., Mareva, M. N., Le, T., Robinson, R. L., Rosen, A. S., & Gelwicks, S. (2006) · Journal of Pain · doi:10.1016/j.jpain.2006.01.443 · Cited by 39
A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
O'connor, A., Noyes, K., & Holloway, R. G. (2008) · PharmacoEconomics · doi:10.2165/0019053-200826120-00007 · Cited by 38
A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms
Gaynor, P. J., Gopal, M., Zheng, W., Martinez, J. M., Robinson, M. J., & Marangell, L. B. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.609539 · Cited by 37
Efficacy and Safety of Duloxetine 30 mg/d in Patients With Fibromyalgia
Arnold, L. M., Zhang, S., & Pangallo, B. A. (2012) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e3182510295 · Cited by 36
Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 33
Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study
Gaynor, P. J., Gopal, M., Zheng, W., Martinez, J. M., Robinson, M. J., Hann, D. M., & Marangell, L. B. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.609540 · Cited by 29
Duloxetine for treating painful neuropathy or chronic pain
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115 · Cited by 29
Self-citation
Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial
Wernicke, J., Raskin, J., Rosen, A. S., Pritchett, Y., D’Souza, D. N., Iyengar, S., Knopp, K. L., & Le, T. K. (2006) · Current Therapeutic Research · doi:10.1016/j.curtheres.2006.10.001 · Cited by 26
Experience and Challenges Presented by a Multicenter Crossover Study of Combination Analgesic Therapy for the Treatment of Painful HIV-Associated Polyneuropathies
Harrison, T. B., Miyahara, S., Lee, A. J., Evans, S. R., Bastow, B., Simpson, D. M., Gilron, I., Dworkin, R. H., Daar, E. S., Wieclaw, L., et al. (2013) · Pain Medicine · doi:10.1111/pme.12084 · Cited by 26
A Randomized Placebo-Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis
Brown, T. R., & Slee, A. E. (2014) · International Journal of MS Care · doi:10.7224/1537-2073.2014-001 · Cited by 25
Principles and practice of pain management
Warfield, C. A. (1993) · McGraw-Hill eBooks · Cited by 25
A Cost-Utility Analysis of Pregabalin Versus Duloxetine for the Treatment of Painful Diabetic Neuropathy
Bellows, B. K., Dahal, A., Jiao, T., & BISKUPIAK, J. E. (2012) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2012.671240 · Cited by 17
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).
Smith, E., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Fadul, C. E., Knox, C., Shapiro, C. L., Gilman, P. B., & Cancer and Leukemia Group B (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.cra9013 · Cited by 15
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).
Smith, E., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Fadul, C. E., Knox, C., Shapiro, C. L., Gilman, P. B., & Cancer and Leukemia Group B (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.cra9013 · Cited by 11
Cautionary tales in the interpretation of systematic reviews of therapy trials
Scott, I. A., Greenberg, P., Poole, P., & Campbell, D. A. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01140.x · Cited by 10
Diagnosis of Diabetic Neuropathy
Veves, A. (1998) · Humana Press eBooks · doi:10.1007/978-1-4612-1816-6_4 · Cited by 8
Efectos de duloxetina y amitriptilina en el dolor neuropático: estudio en 180 casos
Cánovas, L., Miramontes, G. I., Castro, M. C., Mouriz, L., Vázquez-Martínez, A. I., Centeno, J., & Calvo, T. (2007) · Hispana · Cited by 5
Principles and Practice of Pain Management
Kriegler, J. S. (1993) · Neurology · doi:10.1212/wnl.43.8.1635-b · Cited by 5
Does duloxetine safely and effectively reduce the severity of diabetic peripheral neuropathic pain?
Russell, J. W. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0091 · Cited by 4
Fibrinolytic therapy for intraventricular hemorrhage: is the answer becoming clear yet?
Demaerschalk, B. M. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02070.x · Cited by 4
Antidepressant drugs
Mitchell, P. B. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00002-7 · Cited by 1

Research works printed but not linked: 5

Cánovas, 2007, Effects of duloxetin and amitriptilin in neuropathic pain: study in 180 patients, Revista de la Sociedad Espanola del Dolor, 14, 568
Raskin, 2005, Duloxetine in the treatment of diabetic peripheral neuropathic pain - results from three clinical trials, European Journal of Neurology, 12, 221
Skljarevski, 2008, Efficacy of duloxetine in low back pain, European Journal of Neurology, 15, 320
Aronson, 2007, Chapter 2 Antidepressant Drugs, 29, 23
Nagda, 2004, Definitions and Classification of Pain, 51

Sorted by citations

CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
EULAR revised recommendations for the management of fibromyalgia
Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209724 · Cited by 1,566
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917

See all 565

Authors: Lunn, M. P., Hughes, R. A., & Wiffen, P. J.
Affiliations: National Hospital for Neurology and Neurosurgery; Department of Neurology and MRC Centre for Neuromuscular Diseases; Queen Square London UK WC1N 3BG
National Hospital for Neurology and Neurosurgery (GB)
Churchill Hospital (GB)
ORCID: Hughes, Richard AC
Wiffen, Philip J
Venue: Cochrane Database of Systematic Reviews
Publisher: Wiley
Published: 2014-01-03
Volume: 2015
Issue: 10
Pages: CD007115-CD007115
ISSN: 1361-6137 (ISSN-L)
1465-1858
DOI: 10.1002/14651858.cd007115.pub3
PMC: PMC10711341
OpenAlex: W1873305365
Cited by: 565
References: 87
Citations by year: 2026: 19 · 2025: 30 · 2024: 42 · 2023: 42 · 2022: 58 · 2021: 58 · 2020: 53 · 2019: 46 · 2018: 44 · 2017: 57 · 2016: 50 · 2015: 46 · 2014: 19
FWCI: 6.71
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cochrane Database of Systematic Reviews (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute for Health and Care Research (13/89/29)
Medical Research Council (MR/K000608/1)
Topics: Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: duloxetine, serotonin-norepinephrine reuptake inhibitors, peripheral neuropathic pain, diabetic peripheral neuropathy, fibromyalgia, chronic pain, central pain, depression, adverse effects, drug safety, risk of bias, analgesia, stress urinary incontinence, major depressive disorder
MeSH terms: Duloxetine Hydrochloride, Adult, Analgesics, Diabetic Neuropathies, Fibromyalgia, Humans, Neuralgia, Thiophenes, Randomized Controlled Trials as Topic, Chronic Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks